Literature DB >> 3896704

Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis.

J L Blumer, S C Aronoff, C M Myers, C A O'Brien, J D Klinger, M D Reed.   

Abstract

The single dose pharmacokinetics and cerebrospinal fluid (CSF) penetration of ceftazidime were determined in 10 children with bacterial meningitis. Serum ceftazidime pharmacokinetics showed a distinct age dependence in which the clearance in children less than 1 month of age was markedly reduced. Ceftazidime concentrations in CSF, which ranged from 1.4-8.5 micrograms/ml, exceeded the minimum bactericidal concentrations for infecting pathogens throughout the 8-hour sampling period. These concentrations were found to be independent of CSF cell count, protein concentration or the day of therapy on which the study was performed. The ratio of CSF to serum ceftazidime concentration increased with time, suggesting that ceftazidime was cleared more slowly from CSF than from peripheral blood. Our data support the initiation of a study comparing the efficacy of ceftazidime to conventional therapy in children with bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896704     DOI: 10.1159/000457041

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  12 in total

1.  Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.

Authors:  M D Reed; T S Yamashita; C K Knupp; J M Veazey; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics.

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

Review 3.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 5.  Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.

Authors:  R E Kauffman; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 6.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of newborn infants.

Authors:  I Tessin; B Trollfors; K Thiringer; Z Thörn; P Larsson
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 9.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.